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Abstract
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by
chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of
narcotics. This syndrome is under recognized and may be becoming more prevalent. This may be
due in the United States to increases in using narcotics for chronic non-malignant painful disorders,
and the development of maladaptive therapeutic interactions around its use. NBS can occur in patients
with no prior gastrointestinal disorder who receive high dosages of narcotics after surgery or acute
painful problems, among patients with functional GI disorders or other chronic gastrointestinal
diseases who are managed by physicians unaware of the hyperalgesic effects of chronic opioids. The
evidence for the enhanced pain perception is based on: a) activation of excitatory anti-analgesic
pathways within a bimodal opioid regulation system, b) descending facilitation of pain at the Rostral
Ventral Medulla and pain facilitation via dynorphin and CCK activation, and c) glial cell activation
that produces morphine tolerance and enhances opioid induced pain. Treatment involves early
recognition of the syndrome, an effective physician patient relationship, graded withdrawal of the
narcotic according to a specified withdrawal program and the institution of medications to reduce
withdrawal effects.
INTRODUCTION
It has long been recognized that opiates affect gastrointestinal motility. These effects, known
as opioid bowel (or gastrointestinal) dysfunction are manifest as constipation, nausea, bloating,
ileus and sometimes pain (1–3). When pain is the predominant symptom, the condition has
been termed narcotic bowel syndrome (NBS). NBS is characterized by the progressive and
somewhat paradoxical increase in abdominal pain despite continued or escalating dosages of
narcotics prescribed in an effort to relieve the pain. This entity (4–6) was first reported two
decades ago in the United States and 10 years ago in China (7). At the UNC Center for
Functional Gastrointestinal (GI) and Motility Disorders (www.med.unc.edu\ibs), patients are
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frequently seen with chronic and refractory gastrointestinal disorders. Many of these patients
are experiencing the NBS and benefit from narcotic detoxification.
In this narrative review we discuss our experience with the clinical features of this syndrome,
discuss the changing practice of narcotic usage for functional GI pain which may make NBS
more common, review new information on the possible neurophysiological determinants of
the syndrome, offer diagnostic criteria and recommend an approach to management of patients
with NBS. We performed a Medline search and could only identify 4 case reports on this topic
spanning over 20 years. Accordingly, there is a limited and fragmented evidence base and the
references provide supportive evidence for the statements made based on clinical experience.
Nevertheless we consider this to be a rapidly emerging clinical issue that requires attention.
We propose that if the physician recognizes the many facets of NBS with proper diagnosis and
management the clinical outcome can greatly improve and health care costs may be reduced.
DIAGNOSIS
The syndrome is characterized by chronic or intermittent colicky abdominal pain that worsens
when the narcotic effect wears down. While narcotics may seem helpful at first, over time the
pain-free periods become shorter and tachyphylaxis occurs, leading to increasing narcotic
doses. Ultimately, increasing dosages enhance the adverse effects on pain sensation and
delayed motility, thereby initiating the development of NBS.
Although pain is the dominant feature, nausea, bloating, intermittent vomiting, abdominal
distension and constipation are common. Eating can aggravate the symptoms, so when the
condition lasts for weeks, mild weight loss may occur due to anorexia or a willful restriction
of eating out of fear of aggravating the pain (sitophobia). The symptoms may correlate with
delayed gastric emptying and intestinal transit.
A common and misleading consequence of NBS is that abdominal X-rays may show signs
suggestive of a partial intestinal obstruction, which in fact is due to an adynamic ileus or pseudo-
obstruction. There may also be large amounts of fecal retention seen. Laboratory tests including
blood count, amylase, lipase, liver chemistries and urinalysis are usually normal.
The key to the diagnosis of NBS is the recognition that chronic or escalating doses of narcotics
lead to continued or worsening symptoms rather than benefit. However since the symptoms
are nonspecific (4–6), and many clinicians are unaware that narcotic medications can actually
sensitize patients to the experience of pain. Thus, continued treatment with narcotics lead to a
vicious cycle of pain, use of more narcotics and continued or worsening pain. It is not
uncommon for patients to be hospitalized for weeks at a time until they are urged to leave with
a prescription for oral narcotics only to visit the emergency room or be readmitted for the pain
several days later. Table 1 provides the proposed criteria for the diagnosis of NBS.
CLINICAL FEATURES
NBS remains under-recognized due to lack of knowledge about the long-term effects of
narcotics as potentiators of visceral pain and motility disturbances, and difficulties in clinically
distinguishing abdominal pain that results from, rather than is benefited by narcotics. It may
occur among patients with no history of GI symptoms or narcotic use who receive narcotics
to treat persistent post-operative or other types of pain.
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Case #1 - NBS developing after abdominal laparotomy with no prior history of GI symptoms
or narcotic use
A 40 year old lawyer was admitted to UNC Hospitals with acute severe abdominal pain, nausea,
vomiting and fever. There was no prior history of GI illness. Because of marked RLQ
tenderness and leukocytosis, she went to surgery with a presumptive diagnosis of appendicitis,
however the surgery was non-diagnostic. Postoperatively she received up to 40 mg./day of IV
morphine sulfate. Two weeks later while still on the surgery service, she developed worsening
abdominal pain and obstipation with x-ray evidence of a partial small bowel obstruction. At
surgery, she had obstruction from newly developed adhesions and a small portion of bowel
was resected with lysis of adhesions. One week postoperatively she developed peritonitis and
an anastomotic perforation was repaired, her 3rd operation. By this time she had been
hospitalized for 6 weeks and was receiving on average 40–60 mg./day of IV morphine sulphate.
Over the next 2 months the patient remained in the hospital receiving 80 mg morphine sulfate/
day for severe abdominal pain, and nausea with vomiting. Abdominal x-rays and CT showed
small and large bowel dilatation with no evidence for obstruction. By 10 weeks of
hospitalization, a diagnosis of narcotic bowel syndrome was made and the morphine was
withdrawn completely over 6 days. Clonidine 0.1 mg. po 3/day, lorazepam 0.1 mg. 3/day and
desipramine 50 mg. hs was also prescribed, By the time of discharge she reported about 75%
reduction in pain symptoms. It took about 1 additional year for the pain symptoms to completely
resolve, and they have not recurred.
NBS may also occur in patients with functional GI disorders (FGID) who are unwittingly being
prescribed narcotics in an effort to treat the functional GI condition.
CASE #2 NBS in Post-infectious IBS (PI-IBS) (8) with no prior history of narcotic use
A 37 year old female was referred to UNC GI clinic for treatment of chronic abdominal pain,
nausea, vomiting and alternating diarrhea and constipation that began after a salmonella
infection 15 years earlier. Increasing abdominal pain led to frequent emergency room visits,
hospitalizations and 4 abdominal surgeries to diagnose or treat the abdominal pain. In addition,
multiple CT scans, barium enemas, colonoscopy and abdominal/pelvic ultrasounds were also
negative. Her physicians prescribed increasing dosages of narcotics for pain control over a 2-
year period, and when seen in the UNC GI clinic she was taking 90mg/day of morphine sulfate.
The mutual plan was to undertake a controlled withdrawal from narcotics. She unsuccessfully
attempted to stop them on her own and was admitted to UNC hospital with continued nausea,
vomiting, abdominal pain and diarrhea. Lorazepam 1 mg. 4/day was prescribed during the
withdrawal and morphine sulfate was titrated down from 30 mg. to 20 mg 3/day to 10 mg 3/
day for two days at a time and then discontinued. A clonidine patch, 0.2mg was applied 2 days
prior to stopping the morphine sulfate completely. Desipramine and paroxetine were gradually
increased over several weeks. Symptoms were markedly improved at hospital discharge and
three months later she remained off narcotics on desipramine 100mg and paroxetine 20 mg.
with no complaints of abdominal pain, nausea or vomiting. Mild constipation was managed
with polyethylene glycol solution as needed. Nine months later she reported only 3 episodes
of mild abdominal pain and diarrhea that was consistent with her IBS. Several years later she
graduated from law school and is currently in practice with no reports of abdominal pain.
It is noteworthy that patients with pre-existing FGID may be able to differentiate their more
chronic gastrointestinal symptoms from NBS.
CASE #3 – A patient with FGID who developed a different pain due to NBS
A 42 year old female with a history three caesarean deliveries, laparoscopy for lyses of
adhesions and irritable bowel syndrome for 23 years, was referred for treatment for increasing
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pain. The mild and occasional post-prandial cramping became associated over 3 years with
another more persistent chronic lower abdominal pain that seemed different from her more
typical IBS symptom. The new pain was not relieved by defecation, though there was
associated abdominal, bloating nausea, vomiting and depressive symptoms. Notably, during
these 3 years her primary care physician prescribed oxycodone 10 mg TID for the pain. Other
medications included clonazepam 0.5mg TID and paroxetine 60 mg QD for anxiety and
depressive symptoms.
On two occasions she tried to stop the narcotics, but was unsuccessful due to worsening pain.
She was referred to UNC gastroenterology clinic for consultation and agreed to withdraw the
narcotic. She continued with clonazepam and paroxetine and was placed on a clonidine 0.1 mg
3/day for one week, with the oxycodone titrated to 5 mg. twice a day for one week and
discontinued. She then switched from the clonidine patch clonidine pills 0.1mg 3/day. One
year later she was remained off narcotics with no reports of abdominal pain.
Patients with unexplained abdominal pain or functional GI Disorders (FGID) (9) are
particularly vulnerable to erroneous narcotic prescribing particularly when the symptoms are
severe and make urgent requests for pain relief (10) (11;12). Physicians and patients need to
understand the FGIDs as bona fide disorders where symptoms are due to increased motor and
visceral sensory reactivity to stressors with dysregulation of the brain-gut axis, and a close
relationship of the pain to psychosocial distress (13–15). Here, narcotics are contraindicated.
As with case #3, physicians may prescribe narcotics because of the patient’s distress, and the
belief that with no clear explanation for the pain, there are no other treatment options. Up to
30% of patients with FGIDs experience severe, daily symptoms (16) leading them to frequently
visit clinics and emergency rooms for relief and 43% of patients admitted for abdominal pain
are discharged from hospitals with no specific explanation for their pain (17).
The NBS is also prevalent among patients with pre-existing chronic GI diseases (e.g.,
inflammatory bowel disease, pancreatitis, and diverticulitis). Because the pain is easily
attributed to the underlying disorder, the physician may feel justified to use narcotics even
when the disease is not demonstrated to be active, or the patient’s complaints are out of
proportion to the activity of disease. Furthermore, since the adverse effects of the narcotics
may be similar to the GI disease when active, the narcotics are inadvertently continued.
Case #4 – NBS in a woman with Crohn’s disease
A 20 year old female with a 16 month history of prescription narcotic abuse for low back pain
was receiving methadone 260 mg/day from a pain clinic. She developed constipation and right
lower quadrant pain which led to resection of a 6cm right ovarian cystic teratoma. Post
operatively the pain and constipation continued and she was discharged from the gynecology
service on her previous methadone and also oxycodone with acetaminophen prn for
breakthrough pain. She was readmitted to the gynecology service with obstipation. The
methadone was tapered to 230 mg/day and she was given enemas and then released. She
returned 3 days later with nausea, vomiting, bloating, and right lower quadrant pain that was
worse after eating. An abdominal x-ray and abdominal CT scan demonstrated a short segment
of terminal ileum thickening and retained colonic fecal material. Narcotics were re-instituted
for what was presumed to be pain from the Crohn’s disease and the pain got worse.
Colonoscopy showed a non-obstructing terminal ileum that was congested, and ileal biopsies
reported mild chronic active ileitis consistent with Crohn’s disease. A small bowel barium
study demonstrated approximately 20cm of thickened but non-obstructing terminal ileum with
a few proximal skip areas. It was determined by the GI service that although she had Crohn’s
disease, the pain pattern was clinically related to the narcotic bowel syndrome.
Grunkemeier et al. Page 4













She was started on methylprednisolone 40 mg/day and mesalamine 4g/day for the Crohn’s
disease. The methadone was tapered 10–20% each day over 11 days, Duloxetine 30 mg was
started and increased to 60mg/day at one week. Additionally, clonidine 0.1mg 4/day for
narcotic withdrawal control, cyclobenzaprine 10 mg. qhs prn for low back pain and lorazepam
1mg q6hrs for anxiety were initiated. By day 11 she was successfully tapered off methadone
and had dramatic improvement in the pain. Six months later she reported no limitation in
activities and no abdominal or back pain.
Twelve months later she presented with severe iron deficiency anemia, was noncompliant with
the Crohn’s disease medications and had relapsed with the NBS by restarting narcotics for
recreational use and devoloped obstipation and severe abdominal pain. She was admitted to
the medical service and quickly tapered off her methadone over a four day admission and
restarted on treatment for the Crohn’s disease. One month later she had gained all the weight
she had lost, the anemia improved, there was no abdominal pain and daily bowel movements
were normal.
In this complex case, pain was initially thought to be due to an ovarian cyst, though surgery
did not relieve the pain. She was then diagnosed with Crohn’s disease and was treated for what
was thought to be pain due to Crohn’s. However, retrospective review demonstrated worsening
pain symptoms with increased narcotic use. The GI service noted that she had active but non-
obstructing disease, so narcotic withdrawal was instituted. The rapid improvement in pain was
associated with the withdrawal of narcotics on both admissions. The later relapse of NBS was
due to recreational drug use rather than for treatment of abdominal pain or Crohn’s disease and
again the pain resolved with detoxification.
When an underlying GI disease is present, the clinician needs to carefully assess activity of the
disease relative to the patient’s pain behavior to determine the degree to which they are
associated or not. For both FGID and GI diseases, visceral inflammation or injury can increase
afferent signals leading to visceral hypersensitivity. In addition, stress, abuse history, or
psychiatric co-morbidities can also centrally amplify further the perception of even regulatory
visceral signals (18–20). Furthermore (to be discussed) chronic narcotic use by itself can
upregulate nociceptive pathways. This understanding may reduce not only the unwarranted
use of narcotics but also the ordering of expensive and painful procedures which increase the
pursuit of incidental findings not related to the pain including unneeded surgeries as in Case
#4 (e.g., cholecystectomy, hysterectomy or lysis of adhesions) (21). The focus should then be
directed toward proper management.
Finally, there is the risk that a patient with an inactive medical disease may present with severe
pain complaints in order to obtain narcotics.
CASE #5
A 20 year old woman with a history of ulcerative colitis, status post total colectomy and ileal
pouch-anal anastomosis (1 year earlier) and ileostomy takedown ( 9 months earlier) presented
to a local hospital with severe mid-epigastric abdominal pain, and her usual 4–6 bowel
movements/day without blood. A CT scan suggested free fluid in the right upper quadrant and
moderate stool in the J-pouch. She was started on narcotics for the pain and referred to UNC
hospitals for further evaluation and treatment.
On the surgical service, she received IV morphine for the pain that was increased to 90 mg.
per day due to a lack of response. An EGD was normal, and a pouch endoscopy showed
congested mucosa in the ileal pouch and multiple 3–4 mm erosions in the ileum, suggesting
Crohn’s disease. A video capsule could not be completed due to retention in the stomach along
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with food debris due to poor motility. An MRI with MRCP was normal, and an endovaginal
pelvic ultrasound showed bilateral small ovarian cysts.
On the second week of hospitalization she had an exploratory laparotomy because of continued
pain, nausea and vomiting. There was no intra-operative pathology except for adhesions which
were lysed. Post-operatively the pain continued and IV and oral narcotic dosages up to 360
mg./day of morphine equivalent was prescribed. She refused the recommendation to see a
psychiatric consultant. By 7 weeks, the surgeons felt this to no longer be a surgical problem
and with continued severe pain, nausea and vomiting, she was transferred to the medicine
service where she successfully underwent a 5 day narcotic withdrawal program that included
duloxetine 30 mg. qd, lorazepam 1.0 mg. 3/day, quetiapine 100 mg. hs. and clonidine 0.1 mg.
3/day. Just before she was to leave, the nurses found her to be sequestering syringes and needles
under her bed and on one occasion was seen injecting or withdrawing fluid from an IV bag.
After the detoxification the patient stated she still had pain and wanted to go back on narcotics.
She was told that the pain she reported was no different than when she was on high dosages
of narcotics and that to continue on narcotics would be harmful. She stated she would only
leave the hospital if the PICC line remained. After discussion with her family, she agreed to
have the line removed and she was scheduled to come back to GI clinic. The day after discharge
she saw her family physician and was prescribed oxycodone with acetaminophen for pain.
Several days later she was hospitalized at an outside hospital and signed out when the
physicians refused to give her narcotics. She then went to another hospital and received
narcotics for suspicion of bowel obstruction and was then discharged on oral narcotics. Two
weeks later she was seen in the UNC GI clinic; she discontinued the duloxetine because of cost
and desipramine was prescribed for pain control. She acknowledged receiving narcotics from
other sources but denied taking them for two days. Several months later she was seen in
inflammatory bowel disease clinic and denied taking narcotics but a urine toxicology screen
was positive.
Although initially the pain was presumed to be related to complications of her surgically treated
ulcerative colitis, after several weeks it was recognized to be due to narcotic bowel syndrome.
However, treatment was complicated by the patient exhibiting drug seeking behavior. After
detoxification was achieved, she was later thought to be obtaining narcotics from other sources,
thus making restriction from narcotics no longer possible.
PHYSICIAN-PATIENT BEHAVIORS RELATED TO NARCOTICS
The 5 cases, although different in their clinical presentations, share common features relating
to the physician-patient interaction that contributes to the consequence of prescribing escalating
dosages of narcotics (See Figure 1). Typically a patient presents to an inpatient or outpatient
service or to an emergency room with longstanding and unrelenting abdominal pain with
diagnostic evaluations demonstrating no identifiable disorder to focus therapy. Notably for
patients with non-malignant pain, it is the non-verbal communication of pain behaviors over
all other clinical factors including diagnosis and diagnostic studies, that predict the prescribing
of opioids (22). Thus the patient who demonstrates pain and suffering even with negative
evaluations is likely to be prescribed opiates. In addition, existing pressures in the health care
system to see more patients in less time, to discharge as quickly as possible, to utilize expensive
high tech diagnostic and therapeutic tools and to maximize relative value units (RVUs) tend
to reduce the attention paid to patient centered assessment and care, effective communication
skills and proper decision making (23). As a result, this leads to insufficient information
gathering and a confusing understanding of the clinical presentation. The physician may then
embark more upon diagnostic algorithms, imaging scans, and full laboratory panels (23;24),
which are usually negative. The patient is then discharged from the clinical service or
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emergency department with no diagnosis or meaningful treatment plan, and because the patient
still has pain, with a prescription for narcotics. The difficulty is then compounded when the
care is shifted back to the primary care physician because: 1) The accepting physician is not
clear on the diagnosis, 2) he or she may feel conflicted with regard to further prescribing the
narcotics given the recommendations, 3) subsequent dialog between physician and patient on
narcotic use may undercut other treatment options, and 4) the physician may feel unwilling or
unable to manage this clinical situation, or may harbor ambivalent feelings toward the patient.
The patient in turn not being aware of any other option than to request narcotics for pain relief,
feels helpless and possibly angry at the physician when this request is rejected (12).
This all-too-common scenario leads to a maladaptive, physician-patient therapeutic
relationship along with a failure to treat the condition effectively. This pattern of care may also
permit access to the health care system by patients with addictive or malingering behaviors as
demonstrated in Case #5. Only a few of such experiences may sensitize the physician to avoid
seeing patients with NBS, to react in an angry or defensive manner or just “give up” and
indiscriminately prescribe the narcotics. Over time the patient continues to feel dissatisfied and
rejected, and may continue maladaptive behaviors with the prescribing physician or seek
another physician. This vicious cycle can only be broken when the diagnosis of NBS is made
and a narcotic withdrawal program is instituted.
NARCOTIC PRESCRIBING IN THE CURRENT HEALTH CARE SETTING
Impressively, the United States, with 4.6% of the world’s population, uses 80% of the world’s
opioids (25). Although treatments with narcotics for these and other conditions should be both
controlled and limited, prescriptions are actually increasing over time, and associated with this
is an accelerating incidence of narcotic abuse. From 1997 to 2002, there was greater than 400%
increase in retail sales of oxycodone and methadone (25). According to the Natinal Institute
on Drug Abuse (NIDA, www.drugabuse.gov/Infofacts/nationtreatns.html), there has been a
100% increase in hydrocodone associated emergency room visits over a six year span (1993–
1999).
In San Francisco, oxycodone emergency department visits increased 110 percent from 2001–
2002. NIDA has indicated that prescription narcotic abuse continues to be on the rise, is
widespread around the country, and outpaces other drugs of abuse. NIDA’s Community
Epidemiology Work Group (CEWG) report steady increases in oxycodone medical sales,
diversion of the drug from clinics, and increased arrests related to this drug. In 11 of 20 national
metropolitan CEWG areas in 2001, the number of narcotic analgesic-related death exceeded
those for cocaine, heroin/morphine, marijuana, and methamphetamine. Although no data are
available, it is probable that, because of these changes, the incidence of NBS is increasing.
There is evidence that the benefit of increasingly using narcotics for non-malignant pain, and
particularly for functional GI or chronic GI pain is not as great as previously assumed. A recent
systematic literature review found a wide range of methadone dosages prescribed and with
lower than expected effectiveness when used in a variety of chronic or non-malignant pain
syndromes, and the evidence for benefit was based largely on uncontrolled studies (26).
Furthermore, when narcotics are used for functional GI conditions the enhanced sensitivity of
the bowel produce greater GI side effects.
This increased use of narcotics with limited benefit and greater risk seems to be occurring due
to recent changes in prescribing behaviors. Physicians traditionally prescribed narcotics to
younger individuals with acute injuries such as bone fractures, post operative pain, acute severe
pain, intermittent painful syndromes (e.g., migraine), and palliative care of malignant
conditions. In an aging population, recent practice patterns indicate more prolonged treatments
for chronic, non-malignant medical conditions with only limited or no benefit (26).
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Furthermore, even specialized pain treatment centers have modified their narcotic treatment
protocols to include patients with non-malignant pain, including patients with chronic GI
disorders. However, even when protocols are used practitioners do not usually adhere to the
very policies that they have created (27).
In the 1980’s suggestions were made that low dose narcotics combined with a multi-component
pain management program could benefit patients with non-malignant pain and without risk of
addiction (28). Unfortunately, this approach has shifted to primary use of more costly rapidly
absorbed narcotics administered by inhalation or dermal patch, or given parenterally or
intrathecally, at the expense of using the traditional behavioral treatments for chronic non-
malignant pain (29). One study of 690 patients demonstrated over-utilization of prescribed
narcotics such as oxycodone nearly twice as frequently as indicated (30), despite recent
guidelines favoring modalities such as physical and occupational therapy, psychological
treatment, and nonnarcotic analgesics (e.g., antidepressants, gabapentin, ketorolac) before
employing opiates (31). These other modalities are important since it is recognized that patients
with chronic pain report impairments of multiple quality of life measures, including physical
social and psychologic well being (31). Analgesics are only a part of the treatment of chronic
pain and should be used judiciously so as not to encourage passivity amongst patients to engage
in a more complete treatment regimen. (32)
This changing practice pattern is enabled by the greater cost benefit offered by 3rd party payers
who support high volume pain clinics that prescribe narcotics or expensive interventions during
brief visits. This in turn leads to overutilization of health care resources and increased annual
health care expenditures(25), yet there is no evidence that this approach provides any benefit
over multimodality therapy, including behavioral treatments and antidepressants (33).
POTENTIAL PHYSIOLOGICAL MECHANISMS FOR PATHOLOGICAL PAIN
FACILITATION
It is recognized that morphine and other opiates act on opioid receptors in enteric neurons with
a variety of GI effects that includes reduced gastrointestinal and biliary motility and secretion
producing nausea, vomiting, constipation, secondary intestinal pseudo-obstruction and
gastroparesis (34). Furthermore, the cellular mechanisms for opiate tolerance, i.e., reduced
sensitivity to the pharmacological actions of opiates due to chronic exposure are now being
uncovered.
Possibly the most perplexing feature of the NBS is to recognize and accept that narcotic
analgesics can actually cause or aggravate the very pain that is being treated. This
counterintuitive hyperalgesic effect of narcotics relates to the evidence that pain is dynamically
modulated by central nervous system (CNS), neural and opioid pathways that can both inhibit
and facilitate pain perception, and with chronic opiate use neuroplastic changes appear to occur
that paradoxically enhance hyperalgesia and tolerance. Recent studies suggest at least 3
putative mechanisms leading to enhancement of pain experience with the prolonged use of
narcotics: a) the existence of a bimodal opioid regulation system where preferential activation
of excitatory pathways over time may lead to opiate tolerance and pain augmentation, b)
counter-regulatory mechanisms, with release of anti-opioid neuromodulators such as
dynorphin and cholecystokinin (CCK) that oppose opioid anti-nociceptive function, and c)
glial cell activation that produces morphine tolerance and enhances opiate induced pain.
Bimodal (excitatory and inhibitory) opioid modulation system in the dorsal horn
Although activation of opioid receptors is generally considered to produce inhibitory effects
on afferent neurons thus reducing afferent signaling, recent studies (35;36) in mice and in vitro
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indicate that not only can the traditional GI/GO protein inhibitory mode be activated leading
to analgesia but also a newly identified GS protein excitatory receptor can be activated to
produce hyperalgesia depending in part on the concentration and duration of the opioids acting
on the action potential (Figure 2). Thus, there is bimodal (i.e., excitatory and inhibitory)
modulation of the action potential of sensory neurons. In the dorsal horn, low concentrations
of opioids (1–10 ηM) prolong action potentials producing excitatory effects thereby enhancing
neurotransmitter release, while higher concentrations (~1 μM) shorten action potentials thereby
inhibiting neurotransmitter release. When these opioids activate the traditionally recognized
Gi and Go protein, inhibition of neurotransmission occurs that produces analgesia, and
activation of the newly recognized Gs protein activates neurotransmission leading to an
excitation mode that produces anti-analgesia and tolerance(36) (Figure 2). The excitatory
effects of most opioid agonists have been generally overlooked because they are often masked
by the inhibitory effects of the opioids when administered at high (i.e., μM) concentrations
used to produce analgesia. However, it is now recognized that Gs-coupled excitatory opioid
receptors appear to become progressively sensitized during chronic exposure of dorsal root
ganglia to opioid agonists over time leading to tolerance of inhibitory pain effects and
ultimately hyperalgesia. For example, in vitro there is reduced inhibitory (via Gi and Go)
neurotransmitter effects demonstrated with chronic administration of morphine that is due to
the sustained activation of supersensitized excitatory (Gs) opioid receptors (37). These studies
also show that low doses of opiate antagonists like naltrexone, naloxone or buprenorphone
have selective inhibitory effects on the excitatory (Gs) pathways thus enhancing morphine
analgesia(36). Clinically, activation of the excitatory opioid receptor-mediated effects using
prolonged high dose narcotic agonists may help explain its adverse effect of producing opioid
hyperalgesia and the NBS. Conversely, these observations provide the rationale for the recent
release of combination narcotic agonists with low dose narcotic antagonists, the latter serving
to block the excitatory pathways, thus enhancing analgesia with lower dosages of narcotics.
These agents have successfully been used for narcotic detoxification programs as well. The
FDA recently approved Suboxone® (buprenorphine/naloxone) which was evaluated in NIDA’s
Center for Clinical Trials Network (CTN). Through this network, two clinical trials in twelve
community-based treatment programs assessed Suboxone’s efficacy in short-term opiate
detoxification. The clinical trials demonstrated that 68% of patients satisfactorily completed
detoxification and in fact, many of these patients had previously failed other detoxification
programs. Furthermore, it was found to be safe and well tolerated, even when used by
practitioners with minimal experience providing opiate-based pharmacotherapy. (38)
Descending facilitation of pain at Rostral Ventral Medulla and pain facilitation via dynorphin
and CCK activation
Specific regions of the brain, including the cingulate and prefrontal cortex, the Rostral Ventral
Medulla (RVM), and periaqueductal gray modulate incoming pain signals at the level of the
spinal cord. These areas can produce antinociception via descending inhibitory pathways,
effectively attenuating noxious input at the spinal level (39) (18). In addition, the RVM via the
dorsolateral funiculus (DVF) can also activate descending tracts that enhance nociceptive input
at the spinal cord (40). These responses been demonstrated to occur via activation or
inactivation of “on” and “off”cells in the RVM. Activation of the ‘off cells’ produces an
inhibition of nociceptive input, while activation of the ‘on cells’ are believed to facilitate
nociceptive processing within the RVM and descending projections to the spinal cord (41).
Additionally, dynorphin an endogenous opiate when released at the level of the spinal cord is
associated with pain syndromes similar to those seen in chronic inflammation and peripheral
nerve injury. This is thought to occur via increases in excitatory neurotransmitters from primary
afferent neurons, thus provoking a positive feedback loop that amplifies sensory signals (42).
Increased dynorphin is also observed in opiate-induced pain states (43) suggesting its role in
the pro-nociception process, and in animal models, pain behavior is diminished by
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administration of anti-serum to dynorphin (43),(44). Sensitization of sensory
neurotransmission has also been shown when large doses of spinal morphine are released,
leading to paradoxical pronociception, and systemic injection of heroine or morphine can
produce a rebound hyperalgesia after the antinociceptive effects have worn off (45).
Furthermore, CCK and CCK receptors in the CNS overlap with the distributions of endogenous
opioid peptides and receptors and are complementary in modulation of nociception in these
descending pathways. (46) (42) and can facilitate descending pain pathways(47) (48).
The involvement of the RVM in this role of paradoxical pain is demonstrated in a study for
which opiate withdrawal is initiated by naloxone injection, inducing hyperalgesia and
activation of the “on cells,” which can be reversed with lidocaine introduced into the RVM.
(49). Thus, these descending pain facilitatory mechanisms influence morphine-induced
paradoxical pain and may potentiate the pain experience through these mechanisms.
Effects of glial activation on pathologic pain and facilitation by opioids
The activation of spinal cord glia is a new mechanism that has been found to amplify
pathological pain (50). Dorsal horn glia (astrocytes and microglia) when activated produce
hyperalgesia in response to inflammation or infection, drugs such as morphine, from peripheral
injury, or even in response to signals from the CNS, thus opening the possibility for central
effects of stress on peripheral pain facilitation (51). Thus, glial activation can occur from many
noxious sources and can further drive neuropathic pain. Conversely blocking glial activation
can diminish pain. The effect on pain amplification can occur since the glia cell expresses
receptors for many neurotransmitters and neuromodulators, synthesizes and releases numerous
transmitters, and is capable of producing proinflammatory cytokines, such as IL-1, IL-6 and
TNF (50) all of which can enhance pain transmission and even counter the pain inhibitory
effects of morphine.
The concept for glia being mediators of hyperalgesia relate to several lines of evidence(51)
(Figure 3): a) activated glia release nitric oxide, prostaglandins, excitatory amino acids and
growth factors which excite spinal neurons, b) glia can also release substances that enhance
the release of pain transmitters from sensory neurons that synapse in the dorsal horn, , c) glia
are activated by sensory afferents releasing pain neurotransmitters and neuromodulators (e.g.,
ATP, substance P, glutamate and calcitonin-gene-related peptide, nitric oxide, and
prostaglandins) in the dorsal horn, which in turn lead the glia to perseverate in their nociceptive
activity, thus creating a positive feedback loop (50), and finally d) Glia are also activated via
a novel neuron-to-glia chemokine, called fractalkine (51). Fractalkine is expressed on
extracellular surfaces of spinal neurons, and when neurons are excited, they release bound
fractalkine which activates nearby glia (52). Additionally, fractalkine can induce
proinflammatory cytokine release from the dorsal spinal cord (53)
More recently when using colonic irritation in Sprague-Dawley rats to induce visceral
hypersensitivity (54)the introduction of fractalkine, the chemokine specific to neuron to
microglia signaling, facilitated EMG responses to noxious colorectal distension and enhanced
visceral and somatic nociception. This supports the emerging evidence that microglia are
involved in the facilitation of exaggerated nociceptive pain responses to visceral signals.
With regard to the potentiating effect of narcotics on this system, opiates bind directly to glia
via μ receptors causing the release of pro-inflammatory cytokines. Opiates can also act
indirectly on glia via dynorphin release. Chronic administration of morphine, similar to
peripheral nerve injury, increases spinal levels of dynorphin (55) which induces hyperalgesia.
Importantly, this glial activation occurs with chronic, but not acute morphine treatment (56).
Blocking this effect, reduces hyperalgesia, restores analgesia (57) and prevents development
of opiate tolerance.
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Although these findings are relatively recent, they help to support the concept of narcotic
induced hyperalgesia, clinically recognized over 20 years ago, and raise options for future
treatments for chronic pain and the NBS. Further clinical studies are needed to support these
proposed mechanisms in humans and pharmacological studies are needed to demonstrate their
targeted effects on these receptors that amplify the pain experience.
TREATMENT
Our treatment of NBS as summarized in table 3, involves a biopsychosocial approach. An
effective physician patient relationship and a consistent plan of narcotic withdrawal coupled
with the initiation of effective alternative treatments to manage the pain and bowel symptoms
is recommended. Treatment can be initiated when the diagnosis is made and there is reasonable
evidence that no other diagnosis explains the symptoms. NBS is a positive diagnosis which
occurs independent of other pathological conditions, and it may also be the cause of pain in
patients with existing inactive abdominal pathology. Therefore confirming whether any
abdominal pathology is active or inactive is helpful, but an extensive evaluation to “exclude
other disease” is not recommended.
Physician-patient Relationship
An effective therapeutic relationship is the cornerstone of treatment. However, with patients
having NBS, the relationship may be at risk and can become adversarial merely by introducing
the plan to withdraw narcotics. From the physician’s perspective the use of narcotics is
countertherapeutic, and detoxification could improve the clinical outcome. But from the
patient’s perspective, and particularly when no other therapeutic options seem available,
narcotics have been prescribed by others, and at least initially helped to reduce the pain. Thus
the patient may view the physician who withholds narcotics as either questioning the legitimacy
of the symptoms, believing that he or she is addicted, or is rejecting of the patients needs out
of the belief that there is little else to offer, or is using the medical position to control the
patient’s needs (12). Therefore, it is critical to establish an effective therapeutic relationship
before specific treatment recommendations are made. Some approaches to achieving this are
available elsewhere (14;58–61). What follows are some specific features of the relationship
that are relevant to management.
First, the physician must accept the pain as real and validate the personal impact of the pain
using genuine empathy (14;62) (“I can see the pain has really affected your life”). Second the
physician needs to provide information through dialog, rather than by lecturing or providing
written materials. This includes discussion on the physiological basis for the pain relating to
visceral hypersensitivity and the role of brain-gut dysfunction (14;63) in the condition, as well
as the difficulties with taking narcotics: “narcotics slow the bowels and produce the
constipation, bloating and vomiting you are experiencing,” or “narcotics can over time sensitize
the nerves and make the pain worse”. Then the rationale for the treatment plan and the
withdrawal of the narcotics can be explained while gauging the patient’s understanding of the
information. Here it becomes important to also elicit and respond to the patient’s concerns and
expectations about the treatment plan. Although, there is no correct answer to the difficult
questions that may emerge, e.g., “How do you know you’re still not missing something”, “What
if I get a bad pain attack?,” or “What if these other medicines make me sick” certain responses
are in order: a) that the patient has a bona fide disorder that needs to be treated rather spending
more money doing studies, but the clinician will stay vigilant to evaluating new findings should
they emerge, b) to clarify that the treatment is based on a gradual withdrawal of narcotic as
other treatments are substituted, so the patient will not be abandoned in pain, and c) that the
physician will be available to address any side effects or flare ups with the patient if they occur.
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The next step is to gauge the patient’s willingness to undergo treatment by assessing the
genuineness of the response. It is expected that the patient will want to discuss the pros and
cons of the treatment plan and to process this information before coming to a decision. A quick
acceptance (“anything you say doc”) reflects the patient’s desire to meet physician
expectations, or may hide the fact that he or she is not really interested. It is also important to
monitor for unrealistic expectations (“Will this make me pain free?” “If it doesn’t work, can I
go back on narcotics?”), and then provide reasonable and realistic responses. For example, the
physician can state that some patients do become pain free but a more likely effect is that the
patient will feel better off the narcotics than when on them, and that this may improve over
time as additional treatments start to take effect. The treatment plan should also be discussed
with the spouse, parent or other responsible family member, since their understanding of the
process and expectations will help them support the patient during difficult periods.
Communication that the treatment plan involves ongoing “management” of the painful
condition rather than “cure” conveys the physician’s willingness to work with the patient
through the ups and downs that the condition may bring about.
Importantly, the treatment does not end with the narcotic withdrawal program. Emotional
support through continuity of care is essential, and the physician or the physician extender may
need to stay more available for phone calls particularly during the first several weeks after the
withdrawal program has ended. It is reasonable to schedule a follow up visit one or two weeks
afterwards and then monthly for 2 or 3 months.
Specific Treatment Recommendations
The general approach involves a gradual withdrawal of the narcotic, substituting other
treatments that minimize immediate withdrawal effects, treating psychological co-morbidities,
and helping to achieve pain control. The recommendations provided are based on clinical
experience specifically for patients in our functional GI and motility program, and an example
of a withdrawal protocol is presented in Figure 4. It would not apply to habitual users of
“recreational” narcotics or those with drug seeking behaviors (e.g., Case #5) where referral to
more comprehensive psychiatric or narcotic management programs using other protocols
would apply (64;65).
Narcotic Withdrawal Protocol—Patients with nausea and vomiting or intestinal ileus or
pseudo-obstruction (e.g. cases #2 and 4) may require inpatient treatment with a nasogastric
tube for decompression. Conversely, patients using narcotics more chronically for the
abdominal pain can be slowly tapered as outpatients. In situations where the physician
perceives limited motivation and social support, an inpatient withdrawal program may provide
the needed support (case #5).
The time frame of the withdrawal may be influenced by the duration of the narcotic usage and
the dose of narcotics. A patient who develops the syndrome over a short time frame and is
using high dose narcotics prescribed post-operatively should be able to tolerate a shorter
withdrawal period (case #1 and #2). In contrast, a former intravenous drug user who has
subscribed to maintenance methadone therapy with escalating doses may require a longer
course (case #4).
When instituting the withdrawal, the patient should initially be covered with the maximal dose
that will achieve comfort; usually this is the dose chronically being used or is currently being
used in the inpatient setting. Patients taking intravenous dosages should continue with the
intravenous route and then switched over to an oral narcotic equivalent in a few days. Patients
already on oral agents can continue to be withdrawn on oral agents.
Grunkemeier et al. Page 12













Based on our experience, a general guideline is to decrease the starting dosage by 10–33% per
day using a medium to long acting narcotic. The medication should be given in equally divided
dosages in a non-contingent fashion rather than as needed to prevent the effect of acute
withdrawal and to avoid urgent requests for medication for re-emerging pain. For patients
taking shorter acting agents (e.g., oxycodone) conversion to methadone can prevent the effect
of acute withdrawal. However, the shorter acting agents can still be used if the medication is
given more frequently, e.g., every 3 hours. Conversion tables (e.g. with Epocrates®) should be
used to be certain that the dosage with another agent has equal analgesic effects. Using this
method, full detoxification can occur in 3 to 10 days.
Concomitant Treatments—Concomitant medications are used either to prevent
withdrawal symptoms, to reduce anxiety or treat psychological co-morbidity and to provide
long-term central analgesia (Table 4). When a rapid withdrawal is undertaken, usually in the
hospital, the patient’s clinical state needs to be evaluated at least every several hours for the
first day to watch for orthostatic hypotension and syncope, urinary retention or cardiac
arrhythmias. For the first several days it is acceptable to prescribe benzodiazepines which
should be reduced after withdrawal is complete.
Antidepressant An antidepressant should be started prior to narcotic withdrawal and continued
indefinitely. These drugs improve general well-being and abdominal pain (66) (67;68).
However, it is important to help the patient understand that full benefit may not occur for several
weeks. Tricyclic antidepressants (TCA) are favored because their noradrenergic action is
effective in managing pain (69) independent of its antidepressant effects (70), however the
anticholinergic and antihistaminic side effects can lead to constipation and orthostasis. A
secondary amine TCA (e.g., desipramine, nortriptyline) has fewer of these side effects and this
is preferred over the tertiary amine agents (e.g., amitriptyline, imipramine). Lower dosages
(e.g. 50 – 75 mg. desipramine) can be used for analgesic effect unless concomitant major
depression is identified, which would require full dosage.. A serotonin – noradrenergic
reuptake inhibitors (SNRI – e.g., duloxetine) has the advantage of providing pain benefit via
its noradrenergic action, yes does not have the bowel related side effects. Selective serotonin
reuptake inhibitors (SSRI). (e.g., paroxetine, fluoxetine, citalopram), are not generally
recommended since their benefit in pain management is less established.
Benzodiazepine We recommend the temporary use of a medium to long acting benzodiazepine
(e.g. lorazepam, clonazepam) to reduce the anxiety associated with narcotic withdrawal.
Lorazepam 1 mg. q6–8 hours, as an example is begun immediately and given throughout the
withdrawal period. Non-contingent dosing is needed during the weaning period to avoid
breakthrough symptoms of sympathetic activation. The medication should be tapered off when
the narcotic withdrawal is completed.
Clonidine Clonidine, an alpha-2 adrenergic receptor agonist, is effective in reducing the
sympathetic symptoms of narcotic withdrawal including anxiety, restlessness, muscle pains
and chills, (71;72). Clonidine has CNS effects by blocking activity of the locus ceruleus, an
anxiety center (73) and the peripheral intestinal effects by decreasing acetylcholine release
from pre-synaptic terminals thus decreasing the strength, frequency and severity of motor
contractions (74). This agent is started toward the end of the taper as the withdrawal symptoms
start. A typical starting dose is 0.1mg TID and titrated up to the desired effect (up to 0.6mg/
day) while monitoring blood pressure and orthostasis. Particularly for outpatients, a clonidine
patch may be applied for steady dosing and improved compliance. This medication can be
tapered off after narcotic withdrawal or alternatively continued indefinitely, since clonidine
has independent effects on relieving functional GI symptoms including pain and diarrhea
(75;76)
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Treatment of Constipation If patients have constipation and/or pain improves after bowel
movements and there is no evidence for a bowel obstruction, treatment is warranted.
Polyethylene glycol solutions (PEG) act as osmotic laxatives and are a reasonable choice. Other
options include tegaserod (77) or Lubiprostone (78). While these agents have been shown to
be effective in chronic idiopathic constipation, their efficacy in opioid bowel dysfunction has
not been fully studied. Phosphate and magnesium based osmotic preparations or stimulant
laxatives should be avoided because of potential electrolyte disturbances. More recently novel
opioid peripherally acting agents such as alvimopan which blocks the μ receptor (79) and N-
methylnaltrexone are under study and may have benefit for opioid induced constipation and
ileus(80) (81) since they preserve the central analgesic effects while blocking the
gastrointestinal sites of action.
Psychological Treatments Psychological treatment is a rational long-term option, though
there are no studies yet to confirm our clinical observations. Numerous studies do attest to the
value of cognitive behavioral and other therapies in reducing experience of pain symptoms
(82). Ongoing psychological treatment with a specialist in behavioral medicine can provide
benefits. By teaching patients non pharmacologic techniques to manage their symptoms
(distraction, relaxation, and focused attention), patients are helped to achieve a sense of control
over their symptoms. Psychologists can also work with patients to reduce negative thinking
and problem solving that may contribute to an increase in perception of symptoms. Finally,
psychologists often work with patients to develop strategies to address effects of their NBS on
relationships, employment and associated difficulties.
Some patients may become apprehensive or feel threatened by a recommendation to work with
a psychologist. It should be emphasized to the patient that this recommendation does not imply
symptoms of mental illness or narcotic addiction. Rather, it is a component of a comprehensive
approach to the management of their condition and is designed to help reduce their overall
negative symptom experience.
Our treatment program is shown in Figure 4, which assumes a daily narcotic usage of 250 mg.
of morphine equivalent. Prior to the taper of narcotics, a diagnosis must be made and the
physician-patient relationship established. Once the patient agrees to the treatment program,
detoxification begins and the treatments instituted according to the schedule shown. The
treating physician needs to continue with the care of the patient after the detoxification has
occurred.
Issues That May Interfere with a Successful Outcome—Some patients may
“negotiate” on the treatment protocol after it has started, i.e., to request stopping the narcotic
taper for a day or two, or to request more narcotics for a “flare”. Here the physician must
determine if this relates to: anxiety about a possible treatment failure by someone motivated
to continue the treatment, ambivalence or a lack of desire to continue, or in rare cases,
malingering behavior. In all cases, the physician needs to explore and discuss the patient’s
concerns in more detail. The former situation may occur when insufficient attention was paid
to the patient’s concerns before initiating the program and perhaps by not initially having the
patient agree to the protocol. An explanation about the value of continuing the treatment and
the fact that the patient won’t be left alone in pain may help. It is possible to make some
modifications (e.g., to increase the benzodiazepine, reduce the time between narcotic dosing
without increasing the total dose, consider a non-narcotic analgesic such as Ketorolac (83), or
merely to agree to come back for another discussion) that may eliminate the problem. If the
patient seems unwilling to engage in an interactive discussion and only requests narcotics, then
the patient is probably not motivated to continue. As with case #5, this may indicate drug-
seeking behavior, and it is best to stop the program.
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Resistance toward undertaking an unfamiliar or untested treatment strategy may occur,
especially when the narcotic medication has provided some measurable benefit to the patient
at some point. Here, time must be taken to discuss the benefits and risks of the previous course
of treatment before discussing the value of a change. When patients are given an opportunity
to openly discuss the positives and negatives in this manner, they become more aware of the
limitations of the prior treatment, and increases motivation to try something new. (84)
Not infrequently, when detoxification is attempted on an outpatient basis as with Case #3, the
patient may paradoxically taper the narcotic too rapidly or abruptly discontinue it and phone
in distress while experiencing withdrawal symptoms. Here, the patient may not have
understood the withdrawal protocol, was trying to “prove” he or she can do it and wants to get
it over with, or rather was actually unwilling to be on the program and “sabotages” it through
this behavior (“See, it doesn’t work”). Again efforts must be made to explore with the patient
the reasons for this occurrence and then by using that information the physician may proceed
to reinstitute the protocol, hopefully with greater patient motivation.
Patients with NBS may see many physicians for treatment: to find the right physician who can
provide a “cure,” because of a lack of trust of the physicians’ diagnoses, or out of frustration
with demeaning or critical attitudes communicated by other physicians. They may leave the
hospital or the office of the treating physician and go to another physician who may again
prescribe narcotics, especially if he or she is unfamiliar with the withdrawal treatment plan.
Ideally, the treating physician needs to have the patient agree to work with one treating
physician, to identify all the other physicians involved and then send a copy of the clinic note
or discharge summary to them to increase the chance for success with the treatment program.
Any outpatient withdrawal treatment program is confounded by the fact that medical culture
has given license to emergency departments to inadvertently use intravenous narcotics as a
means to quickly treat and discharge the patient with the expectation that the primary care or
referring physician will follow-up. Occasionally the patient may actually be seeing another
physician or presenting to emergency departments for narcotics while allegedly continuing
with the withdrawal program. This behavior is a poor prognostic sign, and supports drug
seeking behavior.
Conclusion
In the United States, narcotics are now one of the most commonly prescribed medications for
pain, and their use is growing. Furthermore, there has been a shift from prescribing narcotics
for acute or malignant pain to chronic non-malignant pain including the FGIDs where patients
are more vulnerable to the development of the narcotic bowel syndrome. NBS occurs when
patients have an increased or unresponsive pain experience along with a variety of GI motility
disturbances related to the narcotics. The diagnosis is based on positive criteria and can easily
be identified. However several factors in combination can perpetuate the failure to recognize
NBS and potentially increase its prevalence in patients with chronic pain. Such factors include
when there is uncertainty in the diagnosis among the patients who exhibit pain behaviors
(“furor medicus”)(24), when a diagnosis is present that “justifies” the use of narcotics, even
when the disease is not active or in rare cases among patients who report severe pain as a means
to obtain narcotics. Furthermore, the health care system can amplify this effect by its focus on
rapid “throughput” and profit margins via diagnostics and procedures to exclude other diseases
rather than by using cognitive skills to understand the patient and problem.
In this paper we describe the diagnostic and clinical features of NBS and an approach to
treatment. We are hopeful that early recognition of the syndrome coupled with a recommended
method to treat the disorder will lead to better patient satisfaction, greater attention to the
physician’s and health care system’s behaviors relating to pain and narcotics and ultimately to
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improved clinical outcomes. The cornerstone of care will depend on an effective physician-
patient relationship.
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Vicious cycle of patient-physician interaction in narcotic bowel syndrome. Patient presents
with a pain, either due to a structural condition (e.g., IBD), post-surgery or functional GI
disorder and narcotics are started. Patient develops symptom of Narcotic Bowel Syndrome.
Subsequent evaluation is unrevealing and the narcotics are escalated to treat the abdominal
pain with worsening of NBS. This prompts the patient to increase health care utilization or
make emergency room visits, which leads to physician frustration and “furor medicusw”
leading to a maladaptive therapeutic interaction with additional use of narcotics. The cycle
continues until the syndrome is recognized and treatment initiated.
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Bimodal (Excitatory and Inhibitory) Opioid Modulation System in the Dorsal Horn. Opioids
appear to have differential effects on the opioid receptor in the dorsal root ganglion based on
whether it activates the traditional GI/GO protein inhibitory mode leading to analgesia or a
newly identified Gs protein excitatory receptor that can produce hyperalgesia. Figure 2a shows
the effect of low dose opioids (1–10 nM), which preferentially activates the excitatory (Gs
coupled) mode and masks the inhibitory (Gi/Go) mode leading to hyperalgesia. More typically
high dose opioids are used (figure 2b) where there is preferential activation of the inhibitory
mode and masking of the excitatory mode. With the chronic use of opioids there is again
sensitization and unmasking of the excitatory mode and tolerance of the inhibitory mode
leading to hyperalgesia. Low doses of opioid antagonists like naltrexone, naloxone or
buprenorphone have selective inhibitory effects on the excitatory pathways which enhances
morphine activity.
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Activation of Dorsal Horn Glial Cells. The activation of spinal cord glial cells leads to
hyperalgesia. This process is enabled via stimulation of glial cells to produce proinflammatory
cytokines, prostaglandin, nitric oxide and excitatory amino acids, which increase neuron
excitability and upregulate NMDA receptors leading to enhanced pain. Factors that activate
this mechanism include. : a) release of Adenosin triphosphate (ATP), nitric oxide (NO),
prostaglandins, substance P and calcitonin g-related polypeptide (CGRP) from sensory afferent
neurons, b) descending signals from the CNS, c) a vicious cycle with activation from other
activated glial cells, d) immune challenges or infections, and e) release of a neuron to glia
chemokine, fractalkine. Importantly chronic opioid use also activates this system via release
of pro-inflammatory cytokines and endogenous dynorphin release. Thus chronic opioid use in
addition to these other factors can lead to hyperalgesia via this mechanism.
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Narcotic Withdrawal Protocol for NBS. After identification of NBS and discussion with the
patient (validating pain, discussion of pathophysiology and willingness to start therapy) the
taper starts with a hypothetical dosage of 250 mg/day and then weaned at a 10–33% reduction
rate per day. Polyethylene glycol (PEG) is used to treat constipation as needed. A tricyclic or
serotonin-norepinephrine (SNRI) antidepressant is started before detoxification and continues
indefinitely for pain control. Lorazepam added at the outset of therapy for withdrawal anxiety
and is discontinued at the end of the narcotic taper. Clonidine is typically added after day 2 or
3 and is continued until withdrawal is completed or for several weeks later. Of paramount
importance is an ongoing physician-patient relationship.
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Table 1
Diagnostic Criteria for Narcotic Bowel Syndrome
Chronic or frequently recurring abdominal pain that is treated with acute high dose or chronic narcotics and all of the following:
• The pain worsens or incompletely resolves with continued or escalating dosages of narcotics.
• There is marked worsening of pain when the narcotic dose wanes and improvement when narcotics are reinstituted (“Soar and Crash”).
• There is a progression of the frequency, duration and intensity of pain episodes.
• The nature and intensity of the pain is not explained by a current or previous gastrointestinal diagnosis*
*
A patient may have a structural diagnosis (e.g., inflammatory bowel disease, “chronic pancreatitis”) but the character or activity of the disease process
is not sufficient to explain the pain.
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Table 3
Overview of Treatment of Narcotic Bowel Syndrome
1 Physician-Patient Relationship
a. Accept the pain as real
b. Provide information through dialog with the patient
i. The physiological basis for the pain
ii. The effects of narcotics on pain and GI function
c. Discuss the rationale for withdrawal
d. Present the withdrawal program
e. Elicit the patient’s concerns and expectations
f. Gauge the patient’s willingness to undergo the program
g. Discuss the treatment plan with a family member
2 Specific Treatment Guidelines







3 Additional Issues to Consider
a. Patient “negotiates” to go back on narcotics
b. Patient rapidly tapers or abruptly withdraws narcotics
c. Patient seeks drugs elsewhere
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Table 4
Treatments for Narcotic Bowel Syndrome
Antidepressants
- TCAs- Desipramine or nortriptyline: 50mg qhs titrated to 150mg qhs,
- SNRIs – Duloxetine: 30mg qd titrated to 60mg qd, Venlafaxine: 37.5mg qd titrated to 225 mg qd
Sympatholytics
- Clonidine: Start 0.1–0.2mg q4hrs as titrated by orthostatic blood pressure
Anxiolytic
Lorazepam: Start 1mg q6hrs or
Clonazapam: Start 0.25mg q8hrs
Spasmolytic
- Hyoscyamine: 0.25mg sublingual q4hrs prn
Cathartic
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